Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.70 USD
+0.10 (1.16%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $8.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
TBPH 8.70 +0.10(1.16%)
Will TBPH be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TBPH
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Best Momentum Stocks to Buy for July 15th
Other News for TBPH
Madison Avenue Partners, LP's Strategic Acquisition in John Wiley & Sons Inc
Unveiling 4 Analyst Insights On Theravance Biopharma
Buy Rating Affirmed for Theravance Biopharma on Yupelri Growth and Ampreloxetine Pipeline Progress
Seth Klarman's Complete Exit from Theravance Biopharma Inc
Theravance Biopharma to Participate in an Upcoming Investor Conference